Fluorine-18-FDG PET/CT demonstrated a decrease in metabolic activity of lymphoma adenopathy, bone marrow, and spleen, after tisagenlecleucel therapy. However, changes in the liver were not statistically significant. These findings suggest that Tisagenlecleucel chimeric antigen receptor T cell (CAR-T) therapy induces a broad systemic metabolic response within the reticuloendothelial system.
Singh et al. (Mon,) studied this question.